Overcoming Capacity Constraints
Drug candidates tend to move through development faster than manufacturers can add production capacity. Building an in-house facility is capital intensive. In this segment, Dave Maheu, VP, Head of Process & Analytical Development at Candel Therapeutics and Curran Simpson, Chief Operating Officer at REGENXBIO share some of ways CGT biotechs can overcome these issues and ultimately get their therapies to patients.
access the Video!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.
Subscribe to Cell & Gene
X
Subscribe to Cell & Gene
Thermo Fisher Scientific Bioproduction
This website uses cookies to ensure you get the best experience on our website. Learn more